All patients (N = 989) | Statistics | ||
Females (N = 545; 55%) | Males (N = 444; 45%) | ||
Overall psychopharmacological treatment | |||
Yes | 498 (94%) | 415 (95%) | Chi2 = 0.811 p = 0.368 |
No | 34 (6%) | 22 (5%) | |
Unknown | 13 (1%) | 7 (2%) | |
Antidepressants | |||
Overall | 295 (59%) | 221 (53%) | |
Tricyclic | 31 (11%) | 28 (13%) | |
SSRI, SNRI, NDRI, NARI | 261 (88%) | 188 (85%) | |
MAO inhibitors | 3 (1%) | 5 (2%) | |
Antipsychotics | |||
Overall | 384 (77%) | 286 (69%) | |
“Typical” | 83 (17%) | 59 (14%) | |
Low-potency | 61 (73%) | 39 (66%) | |
Medium-potency | 0 (0%) | 0 (0%) | |
High-potency | 22 (27%) | 20 (34%) | |
“Atypical” | 356 (71%) | 263 (63%) | |
Mood stabilizers | |||
Lithium | 92 (18%) | 57 (14%) | |
Anticonvulsants | 85 (17%) | 58 (14%) | |
Benzodiazepines | 87 (17%) | 58 (14%) | |
Number of different medication classes per patient | |||
Same class/only one drug | 174 (35%) | 202 (49%) | |
Two drugs | 189 (38%) | 135 (33%) | |
Three drugs | 97 (19%) | 68 (16%) | |
Four drugs | 35 (7%) | 10 (2%) | |
Five drugs | 3 (0.6%) | 0 (0%) |